JP2015518007A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518007A5
JP2015518007A5 JP2015514283A JP2015514283A JP2015518007A5 JP 2015518007 A5 JP2015518007 A5 JP 2015518007A5 JP 2015514283 A JP2015514283 A JP 2015514283A JP 2015514283 A JP2015514283 A JP 2015514283A JP 2015518007 A5 JP2015518007 A5 JP 2015518007A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
schedosporum
schedospodium
prolifenicus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/000487 external-priority patent/WO2013177608A1/en
Publication of JP2015518007A publication Critical patent/JP2015518007A/ja
Publication of JP2015518007A5 publication Critical patent/JP2015518007A5/ja
Pending legal-status Critical Current

Links

JP2015514283A 2012-05-30 2013-05-13 スケドスポリウム属感染症の治療方法 Pending JP2015518007A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902243 2012-05-30
AU2012902243A AU2012902243A0 (en) 2012-05-30 Method of treating Seedosporium spp. infection
PCT/AU2013/000487 WO2013177608A1 (en) 2012-05-30 2013-05-13 Method of treating scedosporium spp. infection

Publications (2)

Publication Number Publication Date
JP2015518007A JP2015518007A (ja) 2015-06-25
JP2015518007A5 true JP2015518007A5 (enExample) 2016-06-30

Family

ID=49672167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514283A Pending JP2015518007A (ja) 2012-05-30 2013-05-13 スケドスポリウム属感染症の治療方法

Country Status (9)

Country Link
US (1) US9867802B2 (enExample)
EP (1) EP2854799B1 (enExample)
JP (1) JP2015518007A (enExample)
CN (1) CN104519882A (enExample)
AU (2) AU2013204604B2 (enExample)
CA (1) CA2874881A1 (enExample)
SG (1) SG11201407924RA (enExample)
WO (1) WO2013177608A1 (enExample)
ZA (1) ZA201408975B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661496A4 (en) * 2017-08-01 2021-04-21 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS WITH SUBSTITUTED NITROSTYRENE COMPOUNDS
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985761A (en) * 1974-10-24 1976-10-12 Sarabhai Research Centre Nitrothiazolyl derivatives of nitrostyrene
JPS585902B2 (ja) * 1978-09-01 1983-02-02 株式会社大塚製薬工場 β↓−ニトロスチレン誘導体
RU2259825C9 (ru) * 2001-06-18 2006-04-10 БиоДием Лимитед Вещества, проявляющие антимикробную, антигрибковую, антипротозойную активности
US20080220103A1 (en) * 2005-10-24 2008-09-11 Jay Birnbaum Method for treating/controlling/killing fungi and bacteria on living animals
MX2008005319A (es) * 2005-10-24 2008-11-04 Staval Pharma Ltd Metodo para el tratamiento/control/exterminio de hongos y bacterias.
WO2008061308A1 (en) * 2006-11-22 2008-05-29 Biodiem Ltd Protein tyrosine phosphatase modulators
EP2293787A1 (en) * 2008-04-25 2011-03-16 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
UA107963C2 (xx) * 2010-06-07 2015-03-10 Janssen Pharmaceutica Nv ПРОТИГРИБКОВІ ПОХІДНІ 5,6-ДИГІДРО-4-$(ДИФТОРЕТИЛ)ФЕНІЛ]-4H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ І 4-(ДИФТОРЕТИЛ)ФЕНІЛ-6H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНУ

Similar Documents

Publication Publication Date Title
JP2015518007A5 (enExample)
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2013014622A5 (enExample)
JP2012255026A5 (enExample)
JP2010529118A5 (enExample)
JP2017536371A5 (enExample)
JP2010132695A5 (enExample)
JP2016518337A5 (enExample)
JP2015524444A5 (enExample)
JP2017515840A5 (enExample)
JP2013538853A5 (enExample)
JP2012136529A5 (enExample)
JP2016540000A5 (enExample)
JP2014062109A5 (enExample)
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
JP2015516452A5 (enExample)
JP2014530847A5 (enExample)
JP2016540799A5 (enExample)
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
JP2010526884A5 (enExample)
JP2015516450A5 (enExample)
JP2016528283A5 (enExample)